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BACKGROUND: This study investigated the potential clinical utility of circulating free DNA (cfDNA) as a source of BRAF mutation
detection in patients enrolled into a phase II study of AZD6244, a specific MEK1/2 inhibitor, in patients with advanced melanoma.
METHODS: BRAF mutations were detected using Amplification Refractory Mutation System allele-specific PCR. BRAF mutation status
was assessed in serum-derived cfDNA from 126 patients enrolled into the study and from 94 matched tumour samples.
RESULTS: Of 94 tumour samples, 45 (47.9%) were found to be BRAF mutation positive (BRAFþ). Serum-derived cfDNA was BRAFþ
in 33 of 126 (26.2%) samples, including in five samples for which tumour data were unavailable. Of BRAFþ tumours, 25 of 45
(55.6%) were BRAFþ in cfDNA. In three cases in which the tumour was negative, cfDNA was BRAFþ. Progression-free survival
(PFS) of patients with BRAFþ tumour and cfDNA was not significantly different compared with tumour BRAFþ but cfDNA BRAF-
negative patients, indicating that cfDNA BRAF detection is not associated with poorer prognosis on PFS in stage III/IV advanced
melanoma.
CONCLUSIONS: These data demonstrate the feasibility of BRAF mutation detection in cfDNA of patients with advanced melanoma.
Future studies should aim to incorporate BRAF mutation testing in cfDNA to further validate this biomarker for patient selection.
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Somatic mutations in the BRAF oncogene have been documented
at a high frequency in cutaneous melanomas, occurring in up to
60% of cell lines and tumour samples (Brose et al, 2002; Davies
et al, 2002). The most documented BRAF mutation is a thymidine-
to-adenine switch at nucleotide position 1799 in exon 15 (Davies
et al, 2002). This encodes for a valine-to-glutamic acid substitution
at amino acid 600 in the kinase domain of the protein (p.V600E,
previously known as p.V599E; Smalley and Herlyn, 2004). The
resulting structural change mimics phosphorylated BRAF and has
an elevated basal kinase activity substantially higher than that for
wild-type BRAF, causing constitutive activation of downstream
signalling in the Ras–Raf–MEK–extracellular ligand-regulated
kinase pathway, which can lead to malignant transformation
(Mansour et al, 1994).
AZD6244 is an orally available, potent, selective, ATP-uncom-
petitive inhibitor of MEK1/2, with pre-clinical activity in BRAF
mutation-positive (BRAFþ) and RAS mutation-positive tumour
models (Yeh et al, 2007). Clinical responses were observed in a
recent 200-patient phase II study of AZD6244 vs temozolomide in
patients with advanced melanoma (study D1532C00003, Figure 1;
Dummer et al, 2008). Six patients randomised to AZD6244 had a
confirmed partial response, of whom five had BRAFþ tumours.
Nine patients randomised to temozolomide had a confirmed
partial response, three of whom had BRAFþ tumours. In
subsequent clinical trials of this drug, patients will be screened
and selected on the basis of the mutational status of their tumour.
In particular, future clinical trials of AZD6244 in advanced
melanoma will evaluate patient selection on the basis of tumour
mutation status.
Mutation status is traditionally assessed by analysis of DNA
extracted from archival tumour tissue samples. However, biopsy
material is not always readily available, even in patients with
metastatic melanoma. Furthermore, limited and degraded amounts
of DNA extracted from tumour biopsies and formalin-fixed
paraffin-embedded (FFPE) tissues present an inherent technical
challenge in mutation detection. If the response to a therapeutic
agent depends on the presence or absence of a particular DNA
mutation, then the availability of tumour-derived DNA for
mutation analysis becomes critically important.
An alternative source of tumour-derived DNA is cell-free or
circulating free DNA (cfDNA). This can be extracted from plasma
and serum, providing an opportunity to develop a less-invasive
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sand more accessible source of tumour DNA for mutation
detection. Previous studies have demonstrated the feasibility of
detecting tumour-specific mutations in cfDNA from patients
with cancer, including detection of epidermal growth factor
receptor mutations in patients with non-small-cell lung cancer
(Kimura et al, 2006, 2007) and KRAS mutations in patients
with pancreatic and colorectal cancers (Sorenson, 2000). More
recently, BRAF mutations have been detected in cfDNA of patients
with melanoma (Daniotti et al, 2007; Shinozaki et al, 2007;
Yancovitz et al, 2007). However, these initial studies included a
small number of patients with only limited numbers of matched
tumour samples.
In this study, we investigated the potential utility of cfDNA for
the detection of BRAF mutation status in a large group of patients
enrolled into the AZD6244 advanced melanoma phase II study to
determine whether cfDNA mutations could be used for patient
selection as an alternative to tissue biopsies.
MATERIALS AND METHODS
Patients and samples
A total of 200 patients with advanced melanoma were enrolled into
study D1532C00003. The study was conducted according to Good
Clinical Practice and the Declaration of Helsinki. All patients
provided written informed consent before participation in the
main study. Consent for analysis of tumour biopsy material was
obtained from all patients enrolled in the study and additional
voluntary consent for collection of serum samples for genetic
analysis was given by 126 patients.
Blood processing for cfDNA extraction
At the time of enrolment, 8.5ml of peripheral blood was taken in a
Becton-Dickinson Vacutainer Serum Collection Tube and gently
inverted for a minimum of five times to ensure a thorough mixing
of the sample. The blood was allowed to clot for 30min and was
centrifuged at 2000g for 10min. The resultant serum supernatant
was transferred to a clean tube and stored at  801C until analysis.
For cfDNA extraction, serum was thawed at room temperature
and cfDNA was extracted from 1ml of serum using a QIAamp
MinElute Virus Spin Kit (Qiagen, Valencia, CA, USA), according to
the manufacturer’s instructions, with the following modifications:
to each 1ml sample of serum, 3mg tRNA (Sigma, Stockholm,
Sweden), 125ml kit proteinase and 1ml kit lysis buffer were added.
After a 1-h incubation, 1250ml of 100% (v/v) ethanol was added.
Each sample was filtered through the MinElute column in aliquots
until the sample was exhausted. Following standard kit wash
procedures (as per the manufacturer’s instructions), the DNA was
eluted twice in 50ml elution buffer.
Germ line DNA extraction
A 9-ml blood sample was collected in a polypropylene tube
containing EDTA and gently inverted for a minimum of five times
to mix the sample thoroughly. Genomic DNA was extracted using
the Nucleon DNA extraction procedure (Tepnel Life Sciences,
Manchester, UK).
Tumour DNA extraction
For analysis of tumour samples, haemotoxylin- and eosin-stained
slides were reviewed by a pathologist to ensure sufficient viable
tumour (as defined by the presence of at least 100 melanoma
cells). DNA was extracted from 40-mm unstained sections of FFPE
samples by digesting the samples in proteinase K (Fluka, Buchs,
Switzerland) for 48h, boiling in 5% chelex (Sigma-Aldrich,
Dorset, UK) and phase extracting through chloroform-and-ethanol
precipitation (Coombs et al, 1999). The DNA was re-suspended
by adding 50ml of 0.1 M TE buffer and was then stored at –201C
until use.
Mutation detection
BRAF mutations were detected using a new Amplification
Refractory Mutation System (ARMS) allele-specific PCR with
Taqman probe assay designed at AstraZeneca (Cheshire, UK)
using in-house software (Newton et al, 1989). The primer and
probe sequences used are shown in Table 1. ARMS primers were
First-line
advanced
melanoma
patients
randomised
(n=200)
AZD6244
100 mg b.i.d.
 continuously  
Temozolomide
200 mg m–2  for
5 days, q28d
Investigator choice of
therapy
Investigator choice of
therapy
May receive AZD6244
Progression-free survival
(primary end point)
Follow-up for
overall survival Efficacy assessment on:
Overall population
BRAF+/no BRAF mutation
BRAF+ or NRAS+/
 no BRAF or NRAS mutation
Primary objective: To compare the efficacy of AZD6244 vs TMZ by evaluation of (i) primary outcome
variable PFS and (ii) secondary outcome variables, including overall survival and
response rate.
Secondary objectives: To assess (i) the primary objectives in BRAF+ patients and BRAF+ or NRAS+
subpopulations and (ii) the safety and tolerability of AZD6244 in this patient population.
1.
2.
3.
Figure 1 Melanoma phase II study design. Abbreviations: BRAFþ, BRAF mutation positive; NRASþ, NRAS mutation positive; PFS, progression-free
survival; TMZ, temozolomide.
Detection of BRAF mutations in tumour and serum samples
RE Board et al
1725
British Journal of Cancer (2009) 101(10), 1724–1730 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sdesigned to detect mutations at amino-acid 600 within the BRAF
gene. The assay can detect p.V600E, p.V600K and p.V600D
mutations within the BRAF gene, but does not distinguish between
them. Control primers were designed to amplify an area of the
BRAF gene with no known mutations or single-nucleotide
polymorphisms. Primer and probe sequences were modified for
the analysis of cfDNA to allow amplification of smaller PCR
products.
Each reaction was carried out in a 25-ml reaction volume
containing 1  Brilliant II PCR mix (Stratagene, Cedar Creek, TX,
USA), 2mM each of BRAF ARMS primer and reverse primer, 0.5mm
BRAF probe, 0.1mm each of control forward and reverse primers,
0.2mM control probe and 0.8mgml
 1 bovine serum albumin. A 5-
ml aliquot of DNA template was added to each reaction. The
reactions were amplified on a Stratagene Mx3000P under the
following conditions: 951C for 10min, followed by 50 cycles of
941C for 45s, 601C for 1min and 721C for 45s. In all cases, samples
were assessed in duplicate.
Data were interpreted as follows: if only the control reaction
occurred with no mutant reaction, the sample was classified as
wild type; if neither reaction occurred, then the sample was
classified as unknown, as the concentration of DNA was below the
limit of detection; if the mutant reaction occurred, the sample was
classified as mutant only if the reaction DCt between control and
mutant reaction was smaller than the DCt for each of the control
wild-type standards on the run to ensure that the mutant reaction
was not simply a nonspecific signal (where DCt is defined as the
difference between threshold cycles (mutation Ct control Ct)). If
there was discordance between the replicates or if the DCt was
within 1 Ct of the DCt cutoff, then the experiment for the sample
was repeated in triplicate, and the sample was considered positive
only if all three replicates were positive.
Positive cell line controls were created using DNA extracted
from the HT29 cell line, known to be heterozygous for the p.V600E
mutation. Human genomic DNA (Roche, Basel, Switzerland) was
used as a non-mutant-DNA-containing negative control and
appropriate reagent control was used in all PCR runs.
All FFPE-extracted DNA samples found to be positive for the
BRAF mutant by ARMS were sequenced to determine the exact
nucleic acid change.
Sequencing reactions for tumour DNA
Tumour DNA was added to duplicate PCR assays containing
primers that amplified BRAF exon 15 (forward primer: 50-TTTC
CTTTACTTACTACACCTC-30; reverse primer: 50-CTTTCTAGT
AACTCAGCAGCATC-30). The resulting PCR products were
sequenced in forward and reverse directions using ABI BigDye
sequencing and analysed using SeqScape (Foster City, CA, USA). A
mutation result was accepted if it was present in both forward and
reverse sequencing traces, and in duplicate PCRs (to eliminate
false-positive mutations occurring because of sample fixation
artefacts).
Cloning and sequencing for BRAF mutations
To confirm the presence of BRAF mutations in cfDNA from
samples in which cfDNA was BRAFþ but the matched tumour
sample was negative for a mutation by ARMS, cfDNA was
extracted from 1ml of serum and cloned and sequenced for the
presence of BRAF mutations. Cloning was performed using the
TOPO TA Cloning kit (Invitrogen, Paisley, UK) (containing pCR
2.1-TOPO) with chemically competent Escherichia coli strain TOP
10F’ (Invitrogen, Paisley, UK). PCR products containing the BRAF
sequence were obtained using the same primer sequences and
conditions as those used for exon 15 BRAF sequencing as
described above. A mutation result was accepted if it was present
in both forward and reverse sequencing traces.
Reproducibility of BRAF detection in cfDNA over 1 year
The reproducibility of BRAF detection in cfDNA was tested in 24
serum samples stored at –801C for 6 months, 13 of which were
positive for BRAF mutations on initial sampling. A separate set of
24 serum samples stored at  801C for 12 months were re-tested for
BRAF mutations, 17 of which were positive for BRAF mutations on
initial sampling.
The reproducibility of BRAF detection in cfDNA stored at
 201C for 6 months was tested on 26 samples, 17 of which
had tested positive for BRAF mutations at the initial analysis.
The reproducibility of BRAF detection in cfDNA stored at  201C
for 12 months was tested on a further set of 24 samples, 16 of
which had tested positive for BRAF mutations at the initial
analysis.
Biostatistical analysis
The primary end point in study D1532C00003 was PFS and, similar
to the primary analysis for this study, a multivariate analysis of
PFS was carried out for those patients with serum results, using the
Cox proportional hazards model allowing for the effect of
treatment and adjusting for the following covariates: lactate
dehydrogenase (LDH; X2  upper limit of normal (ULN) vs
o2 ULN); BRAF mutational status by cfDNA; World Health
Organization (WHO) performance status (WHO PS; 0 vs 1, 2) and
tumour type (uveal vs non-uveal).
To assess whether allowing cfDNA-detected BRAFþ patients
into a selected trial would result in the study population being
enriched for patients with differing prognoses from the main study
population, analyses were carried out using patients who were
BRAFþ by tumour but with serum results also available. A
univariate analysis was carried out to compare PFS between
patients who were BRAFþ in serum and patients in whom BRAF
mutations were not detected. In addition, summary 2 2 tables
were produced to assess a potential correlation between BRAFþ,
as detected by cfDNA, and the known prognostic factor LDH.
Table 1 Primer and probe sequences
ARMS assay ARMS primer (50-30) Common primer (50-30) TaqMan probe (50-30) Size (bp)
BRAF for FFPE
1799T4A
AAAAATAGGTGATTTTGGTCTA
GCTACATA
TAGTTGAGACCTTCAATGACTTT
CTAGTAA
Yakima Yellow –AATCTCGATGGAGT
GGGTCCCATCAGTTTGAACA-Bhq
179
Control for FFPE AGGACACCGAGGAAGAG
GACTT
GGAATCACCTTCTGTCTTCATTT Cy – CCATCTTCTTCCTGCCTGATGA
GGGGAAA-Elle
252
BRAF for cfDNA AAAAATAGGTGATTTTGGTCTA
GCTACATA
CATCCACAAAATGGATCC
AGACAA
Yakima Yellow – GATGGA+GTGGGTC+
CCATC+AG-Bhq
91
Control for cfDNA CTCCAGATCTCAGTAAGG
TACGG
GGGAAAGAGTGGTCTCTCATC Cy5 – CATGA+AG+AGATTAAT
GGCAG+AGTG+CC-Elle
101
Abbreviations: ARMS¼Amplification Refractory Mutation System; cfDNA¼circulating free DNA; FFPE¼formalin-fixed paraffin embedded tissues.
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sLDH levels were available for 190 of the 200 patients enrolled into
the study.
RESULTS
Assessment of BRAF assay sensitivity
Using the cell line HT29 (known to be heterozygous for the
p.V600E mutation), several serial dilution studies of HT29 DNA in
human genomic DNA were performed to determine the sensitivity
of the BRAF ARMS assay. The BRAF mutant could be detected at a
level as low as 5 copies of HT29 DNA in a background of 5000
copies of wild-type DNA (0.1% sensitivity, data not shown).
BRAF p.V600 mutation detection in clinical samples
Of the 200 patients enrolled in the trial, 176 tumour samples were
obtained; 163 samples were FFPE and the remaining 13 were fresh
frozen specimens. Of the 176 tumour samples analysed, 158 (90%)
generated acceptable ARMS results. DNA sequence data for BRAF
were obtained for 147 (84%) tumour samples. In total, 70 BRAF
mutations in tumour DNA were identified by ARMS (70 of 158
(44%)). Of the BRAF mutations detected by ARMS, five were
determined by sequencing to be complex g.1798-1799GT4AA
changes resulting in a BRAF p.V600K alteration, rather than the
more common p.V600E (g.1799T4A). Sequencing detected two
samples with additional mutation types that could not be captured
using the specific ARMS assays in this study: BRAF g.1742A4T
(p.N581S) and g.1801A4G (p.K601E). Eighteen mutations were
detected by ARMS but failed DNA sequencing because of low DNA
yields, indicating that ARMS is the more robust method,
particularly for analysis of DNA extracted from FFPE specimens;
although confined to detecting known mutations.
Of the 96 tumour samples available from patients with cfDNA
data, 45 (47%) were detected to be BRAFþ by ARMS. Sequencing
had confirmed these mutations to be p.V600E in 42 cases and
p.V600K in 3 cases. A further tumour sample was shown to
harbour a p.K601E mutation, which was not detectable by the
ARMS assay design.
Serum samples were available for 126 of the 200 patients
enrolled in study D1532C00003; cfDNA was extracted from
samples as described and analysed for the presence of a BRAF
mutation (results summarised in Table 2).
In total, 33 (26%) BRAF mutations were detected in cfDNA by
ARMS. Of the 126 patients with serum samples, 96 had matched
tumour data available. For the remaining 32 patients, tumour data
were unavailable either because there was no available tumour
sample (n¼20) or because analysis had failed because of
insufficient DNA extracted from the tumour sample (n¼10).
Five cfDNA samples were positive for a BRAF mutation in which
no tumour data were available. Of the BRAFþ tumours, 25 out of
45 (56%) had BRAF mutations detected in the serum. In three
samples, BRAF mutations were identified in the serum but the
tumour was BRAF mutation negative. For each of these samples,
cfDNA was extracted from a further 1ml of serum for repeat
analysis; in all samples, a BRAF mutation was confirmed. In two of
these cases, sufficient serum was available to allow extraction of
cfDNA from a further 1ml of serum, and the resultant cfDNA was
cloned and sequenced for the presence of BRAF mutations. In both
these cases, BRAF mutations were confirmed in these samples with
13 and 7% of clones positive for a mutation.
In total, of the 96 cases with matched tumour and cfDNA data,
the concordance in BRAF mutation detection was 76% (95%
confidence interval 66–84%). If a BRAF mutation was present in
tumour DNA, the pick up rate in cfDNA was 56% (95% confidence
interval 40–70%).
Importantly, in all samples, analysis of germ line DNA by ARMS
was negative for BRAF mutations, confirming that any BRAF
mutations detected were tumour derived.
Reproducibility
The reproducibility of BRAF detection in cfDNA was tested in 24
serum samples stored at  801C for 6 months and a further 24
serum samples stored at  801C for 12 months. All serum samples
analysed after 6 months storage yielded BRAF mutation results
identical to the initial analysis. After storage for 12 months, 21 of
the 24 serum samples yielded BRAF mutation results identical to
the initial analysis. In two samples, the BRAF mutation was no
longer detected and, in one sample, a BRAF mutation was detected
when initial analysis had been negative. In all of these cases, the
tumour sample had been positive for a BRAF mutation.
The reproducibility of BRAF detection in cfDNA stored at
 201C for 6 months was tested on 26 samples, 17 of which had
tested positive for BRAF mutations at the initial analysis. At repeat
analysis, 16 of the 17 samples that had previously been found to be
positive were still BRAFþ. The one negative sample had
previously been positive with a high DCt, suggesting low levels of
BRAF mutations within the sample. This patient was known to
have a BRAFþ tumour. A further sample tested positive for a
BRAF mutation when previously it had tested negative. Again, the
DCt of this sample was high, suggesting low levels of mutant BRAF
within the sample.
A similar result was observed after analysis of 24 DNA samples
stored for 12 months at  201C. Of the 16 samples previously
BRAFþ, all were BRAFþ after 12 months. A further sample was
positive for a BRAF mutation in which initial analysis had been
negative with a high DCt; this sample was from a patient known to
have a BRAFþ tumour. These data imply that in some samples the
level of BRAF mutations is very low and sampling differences
during analysis could explain the discordant results.
cfDNA as a prognostic indicator
The PFS of the 126 patients with cfDNA results did not differ
significantly from the PFS of the study D1532C00003 population as
a whole (data not shown). BRAF status by tumour sample (in the
primary analysis of 200 patients) or cfDNA (n¼126) was not
shown to be a prognostic factor for PFS (data not shown). In
addition, in those patients with BRAFþ tumours, in whom serum
was available for analysis, there was no difference in PFS between
patients in whom BRAF mutations could be detected in the serum
compared with those patients in whom cfDNA BRAF mutations
were not detected (n¼45, HR 1.08, 80% confidence interval 0.69,
1.68, two-sided p value¼0.826, Figure 2). This suggests that the
presence of detectable mutant BRAF in serum of patients with
BRAFþ tumours is not associated with a poorer prognosis on the
basis of PFS compared with patients with BRAFþ tumours in
whom BRAF mutations are not detected in cfDNA .
LDH levels were available for 190 patients enrolled in study
D1532C00003. Consistent with previous literature, ULN had a
Table 2 Summary of BRAF mutation analysis of tumour and cfDNA in
n¼126 patients
Tumour DNA
BRAF
positive
BRAF
negative
BRAF
unknown Total
cfDNA BRAF positive 25 3 5 33
BRAF negative 20 46 27 93
Total 45 49 32 126
Abbreviation: cfDNA¼circulating free DNA.
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sworse prognosis on PFS for patients in the study with an LDH level
greater than 2x than it did for patients with lower LDH levels. The
proportion of patients with BRAF mutations in the serum was
greater in the elevated LDH group compared with that of patients
in the study as a whole (24 vs 16%; Table 3) However, if patients
with high LDH are excluded from future trials, preselecting on
cfDNA BRAF serum status will not enrich for poor prognosis
patients (as defined by LDH4 2 ULN).
DISCUSSION
This study has demonstrated the detection of BRAF mutations in
cfDNA extracted from the serum of patients with advanced
melanoma enrolled in a phase II study of AZD6244 versus
temozolomide. The concordance rate of cfDNA BRAF mutations
with tumour BRAF mutations was 56%, which is consistent with
that of other reports (Daniotti et al, 2007; Yancovitz et al, 2007).
Although other groups have demonstrated the feasibility of
detecting BRAF mutations in serum and plasma of patients with
melanoma (Daniotti et al, 2007; Shinozaki et al, 2007; Yancovitz
et al, 2007), this is the first study that compares tumour and cfDNA
results from a large cohort of patients and demonstrates the
potential clinical application of cfDNA mutation detection for
patient selection within clinical trials.
Yancovitz et al demonstrated BRAF mutations in cfDNA
extracted from plasma of 14 of 26 (54%) stage IV melanoma
patients (Yancovitz et al, 2007). Of 17 available tissue samples, the
concordance of results was 10 of 17 (59%). Daniotti et al compared
cfDNA and tumour BRAF mutations in 20 patients and found that
cfDNA was positive for a BRAF mutation in 5 of 13 cases in which
the tumour harboured a BRAF mutation (Daniotti et al, 2007).
Shinozaki et al demonstrated BRAF mutations in 38 of 103 (37%)
patients with melanoma (Shinozaki et al, 2007). However, they do
not record any tumour data to assess concordance of their assay.
Our series identified three cases in which cfDNA was positive for
a BRAF mutation but the tumour DNA was negative. Yancovitz
et al and Daniotti et al both identified two patients in whom BRAF
mutations were detected in cfDNA but not in tumour DNA
(Daniotti et al, 2007; Yancovitz et al, 2007). Often, tumour BRAF
status is derived from a primary lesion that occurred months or
years earlier. In our study, the source of tumour material, whether
primary or metastatic, was not captured. It is possible that the
BRAF status of metastatic tumour is different compared with that
of primary tumour. However, BRAF mutations are thought to
develop early in the pathogenesis of melanomas, and analyses of a
series of paired primary and metastatic lesions from the same
patients indicate that BRAF mutations are preserved in metastases
(Omholt et al, 2003). Heterogeneity in BRAF mutation status
between metastatic sites may exist (Chang et al, 2004), and thus
cfDNA might provide a more accurate representation of BRAF
mutation status within a patient than a biopsy of any single lesion.
In this regard, three samples in this study had BRAF mutations
detected in the serum, wherein the tumour was BRAF mutation
negative. In two of these samples, the DNA yield from the tumour
sample was very low, and in the third sample, histological
evaluation of the tumour sample revealed only small amounts of
melanoma. Therefore, the difference in mutation results between
tumour and cfDNA in these cases may be explained by the fact that
the tumour DNA for these samples was not representative of the
tumour as a whole. This again highlights the technical challenges
in mutation detection in tumour DNA. In two of these three cases,
there was sufficient remaining sample to be able to confirm the
presence of BRAF mutations in cfDNA by cloning and sequencing.
These data increase confidence that the BRAF mutation was indeed
present in cfDNA and that the tumour results are either false
negative due to sampling error or not reflective of the mutation
status of the metastatic disease.
When considering the use of cfDNA mutation detection as an
inclusion criterion for clinical trials, we needed to ascertain
whether there was a different overall outcome in those patients
with mutant cfDNA compared with those patients with tumour
mutations but no cfDNA mutations. If this were the case, then
enrolling patients on the basis of cfDNA results may enrich trials
for patients with a differing prognosis. Our series has demon-
strated that the prognosis by PFS of patients with BRAFþ
tumours, in whom BRAF mutations can be detected in cfDNA, is
not significantly different from that of patients with BRAFþ
tumours in whom BRAF mutations cannot be detected in cfDNA.
This increases our confidence that enrolling patients into clinical
trials on the basis of cfDNA mutation results will not enrich our
trial populations for cohorts of patients with an inherently worse
prognosis.
Although this study has provided meaningful and interesting
results, there are important limitations to this work that require
acknowledgement and discussion. First, 191 of the 200 patients
enrolled in study D1532C00003 had stage IV melanoma. It is
suggested that the detection of cfDNA mutations is tumour-stage
dependent, with decreased accuracy in earlier-stage patients.
Daniotti et al reported BRAF-positive cfDNA results in 3 of 13
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Figure 2 The presence of circulating BRAF mutations does not effect
progression-free survival. There was no difference in PFS between patients
in whom BRAF mutations could be detected in the serum compared with
those patients in whom cfDNA BRAF mutations were not detected. HR
calculated using an unadjusted Cox proportional hazards model.
Abbreviations: BRAFþ, BRAF mutation positive; cfDNA, cell-free DNA;
HR, hazard ratio; CI, confidence interval.
Table 3 Correlation of BRAF mutations in cfDNA with poor prognostic
factors (lactate dehydrogenase)
CfDNA patients (n¼126);
serum mutation results
Total study
LDH
BRAF positive
(n¼33)
BRAF negative
(n¼93)
population
(n¼200)
LDHo2XULN 24 (73%) 82 (88%) 158 (79%)
LDH¼2 ULN 8 (24%) 8 (9%) 32 (16%)
LDH unknown 1 (3%) 3 (3%) 10 (5%)
Abbreviations: cfDNA¼circulating free DNA; LDH¼lactate dehydrogenase;
pts¼patients; ULN¼upper limit of normal.
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sstage IV melanoma patients but in none of 4 stage I/II
patients (Daniotti et al, 2007). This ‘stage-dependency’ may
restrict cfDNA as a detection method in trials of agents for
advanced disease, although more sensitive technologies may alter
this in the future.
Second, it should be noted that in the D1532C00003 trial,
cfDNA analysis was conducted using serum, which contains high
levels of contaminating wild-type DNA sequences after white cell
lyses in the clotting process, which may interfere with mutation
detection sensitivity. The alternative, plasma, which is processed
from blood collected in a tube containing an anticoagulant,
contains fewer wild-type DNA sequences and is hence a more
sensitive medium for cfDNA mutation detection (Daniotti et al,
2007). The use of serum in our study could have reduced the
mutation detection rate in cfDNA and our future trials will collect
plasma for this purpose.
Third, concern has been raised with regard to the reliability of
cfDNA mutation detection in stored blood samples (Sozzi et al,
2005; Daniotti et al, 2007). Previous reports have demonstrated
that cfDNA mutations are no longer detectable in previously
positive serum and DNA samples after 12 months of storage
(Daniotti et al, 2007). In this series, mutation detection was not
found to be significantly affected by 6 months of storage of serum
samples. However, after 12 months of storage of serum at  801C,
there were three discordant results. Discordant results were also
noted when cfDNA extracted from serum was stored at –201C for 6
or 12 months. In all of these cases, DCt for the mutation assay was
high, suggesting that there was a low proportion of mutant DNA
within those samples. This might explain the discordant results;
simple sampling differences at the time of the BRAF assay may
have affected detection. In this series, insufficient sample was
available for extensive repeat testing, but these results raise some
concern regarding the reliability of mutation detection in cfDNA
with low levels of mutant DNA in the sample, especially in stored
samples. Future studies will need to focus on repeated testing of
initial samples to fully establish the reliability and precision of
these tests. The use of plasma or more-sensitive technologies in
future trials may reduce the number of samples with discordant
results on repeated testing.
Finally, and importantly, not all patients with BRAFþ tumours
had BRAFþ cfDNA. As discussed, it is possible that there are
some differences in the mutation status between primary tumour
and metastatic deposit, but the most likely explanations are that
either the tumour cfDNA is shed at such a low level that it is below
the sensitivity of the assay or there are true biological differences
between tumours in different patients, indicating that cfDNA is
shed at a higher level in some patients than in others. Recent
reports from a study of cfDNA mutations in patients with operable
colorectal cancer using an ultra-sensitive technology (BEAMing)
suggest that mutated cfDNA fragments are present at levels as low
as 0.18% (Diehl et al, 2008). Development of these increasingly
sensitive technologies may improve detection rates in the future.
Although the exact source and nature of cfDNA remain unclear,
the potential applications of its use are becoming increasingly
apparent. It offers significant advantages over tumour DNA
analysis: it is less invasive than tissue biopsies and results are
quicker to obtain (particularly within clinical trial scenarios when
tissue samples are often spread across many sites and countries).
In addition, cfDNA can provide us with the opportunity to detect
the current or real-time mutation status of a tumour and
ultimately could lead to serial sampling to assess tumour
progression or the development of resistant mutations. This study
has demonstrated that cfDNA analysis could provide an opportu-
nity for the detection of tumour-specific mutations in patients with
advanced melanoma, allowing for speedy access to novel agents
and enrolment into clinical studies without waiting for tissue
procurement. This technology provides patients who have no
available tissue samples with the opportunity to be considered for
a study without having to undergo further invasive procedures to
obtain tissue samples. The study has demonstrated that the
detection of BRAF mutations in cfDNA is not significantly
prognostic in advanced melanoma, and that, provided high LDH
patients are excluded from the study population, entering patients
by cfDNA analysis into a BRAFþ-selected trial will not enrich for
a poor prognostic study population. Further studies on AZD6244
and other targeted agents will focus on improving the tissue/
cfDNA concordance rate and will aim to further validate cfDNA as
a surrogate marker for tumour DNA mutations and as an inclusion
criterion for clinical studies.
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